December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Post hoc exploratory analysis identified potential predictors of response to tazemetostat in patients with relapsed/refractory follicular lymphoma with WT and mutant EZH2, including rituximab refractoriness.